NCT05758207

Brief Summary

The aim of this study was to evaluate the prevalence and types of oral complications found in patients diagnosed with haematological malignancy

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 17, 2023

Completed
18 days until next milestone

First Posted

Study publicly available on registry

March 7, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

May 15, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

August 15, 2023

Status Verified

May 1, 2023

Enrollment Period

7 months

First QC Date

February 17, 2023

Last Update Submit

August 13, 2023

Conditions

Hematologic Malignancy

Outcome Measures

Primary Outcomes (1)

  • Calculate the prevalence of oral complications.

    Calculate the prevalence of oral complications with special attention to infectious complications in hematological malignancy patients.

    Baseline

Secondary Outcomes (1)

  • the morbidity related to oral complication in haematological malignancy patients.

    Baseline

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All newly diagnosed patients elder than 18 years with hematological malignancy

You may qualify if:

  • All newly diagnosed patients elder than 18 years with hematological malignancy start from January 1st 2022 to January 1st 2023 including Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Chronic lymphoblastic leukemia Non-Hodgkin lymphoma Hodgkin lymphoma Multiple myeloma

You may not qualify if:

  • Patient younger than 18 years old Patients previously diagnosed Patients refused to participate in our study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university

Asyut, Egypt

RECRUITING

Related Publications (2)

  • Emodi O, Ohayon C, Bilder A, Capucha T, Wolff A, Rachmiel A. Postextraction Mucormycosis in Immunocompromised-Patient Management and Review of Literature. J Oral Maxillofac Surg. 2021 Jul;79(7):1482-1491. doi: 10.1016/j.joms.2021.01.019. Epub 2021 Jan 25.

    PMID: 33617788BACKGROUND

  • Elad S, Zadik Y, Yarom N. Oral Complications of Nonsurgical Cancer Therapies. Atlas Oral Maxillofac Surg Clin North Am. 2017 Sep;25(2):133-147. doi: 10.1016/j.cxom.2017.04.006. No abstract available.

    PMID: 28778303BACKGROUND

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Nabila Fayek

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Merit Rafeek

CONTACT

01270240012toot.rafeek@gmail.com

Mai Mostafa

CONTACT

01223971678Mai_heamatology@aun.edu.eg

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

February 17, 2023

First Posted

March 7, 2023

Study Start

May 15, 2023

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

August 15, 2023

Record last verified: 2023-05

Locations

EG(1)